Key Highlights

  • Shares are trading 7.73% higher at $3.11 on Wednesday, October 28, 2026.
  • The third-quarter net loss was $15.636 million, or $0.12 per share, against an estimated loss of $0.14.
  • Cash, cash equivalents and investments totaled $114.3 million at September 30, 2026.
  • Total operating expenses rose about 10% to $16.947 million.
  • Voyager instrument availability is planned for the middle of 2027, with twenty proteoform assays planned through mid-2028.

Nautilus Biotechnology Shares: Is Tuesday's Quarterly Report Behind the Climb?

Nautilus Biotechnology (NASDAQ:NAUT) shares are trading 7.73% higher at $3.11 on Wednesday, October 28, 2026, which puts the implied prior close near $2.89 (calculated from the price and percentage). The move comes one session after the company reported third-quarter results on Tuesday, October 27. No separate company announcement dated today accompanied the gain.

Because the stock sits below $5 and rose more than 3%, it features among the most actively traded penny stocks. Using the roughly 130 million weighted shares implied by the quarterly loss and loss per share, the market value works out to about $400 million (calculated, approximate).

Nautilus is developing a platform that measures proteins and their many variants, known as proteoforms, with the aim of mapping them at scale in health and disease. Its Voyager instrument and Iterative Mapping method are still in development and not yet sold commercially.

The quarterly loss was $15.636 million, or $0.12 per share, compared with $13.574 million, or $0.11, a year earlier. The result was narrower than the estimated loss of $0.14 per share.

Cash Position: How Far Does $114.3M Go After a $41.8M Decline This Year?

Cash, cash equivalents and investments stood at $114.3 million at September 30, down about $41.8 million from roughly $156.1 million at the end of 2025. The release did not state a runway figure.

Cash used in operations over nine months was $40.1 million, against $38.3 million a year earlier. By a simple calculation, that pace annualises to about $53 million, or roughly two years of operating burn.

Total assets were $148.9 million, liabilities were $32.4 million and stockholders' equity was $116.6 million. The nine-month net loss was $44.802 million, or $0.35 per share, versus $45.220 million, or $0.36.

Costs and Revenue: Why Did the Quarterly Loss Widen About 15%?

Total operating expenses rose about 10% to $16.947 million from $15.472 million. Research and development was $10.176 million, up about 6%, while selling, general and administrative expense climbed about 15% to $6.771 million on higher laboratory, professional services and payroll costs.

Interest income fell to $1.173 million from $1.903 million, which helped widen the net loss by about 15%. Over nine months, research and development spending fell about 6% to $29.496 million.

Revenue was $234,000, made up of $208,000 of grant revenue and $26,000 of service revenue from an early access program. There was no revenue in the third quarter of 2025. After quarter end, the company joined a four-year ARPA-H consortium called SEEDS and expects up to $6 million to deploy Voyager in Alzheimer's disease and cancer research, though the release warns the funding could be reduced, delayed or ended.

What to Watch Next: Can Voyager Stay on Track for Mid-2027?

The company said a published scientific paper described how Iterative Mapping reveals proteoforms tied to disease, and it shared first oncology assay data, including AKT1, at World HUPO 2026. Management said performance matched the earlier Tau assay. The release offered no full-year financial guidance and cautioned that timelines could slip. The next markers are the mid-2027 instrument date, further assay releases through mid-2028, progress on SEEDS and the pace of operating expense growth.